DK2476667T3 - Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer - Google Patents
Aminoheteroaryl-forbindelser som proteinkinase-inhibitorerInfo
- Publication number
- DK2476667T3 DK2476667T3 DK12163855.5T DK12163855T DK2476667T3 DK 2476667 T3 DK2476667 T3 DK 2476667T3 DK 12163855 T DK12163855 T DK 12163855T DK 2476667 T3 DK2476667 T3 DK 2476667T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein kinase
- kinase inhibitors
- heteroaryl compounds
- amino heteroaryl
- amino
- Prior art date
Links
- 125000005214 aminoheteroaryl group Chemical group 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44958803P | 2003-02-26 | 2003-02-26 | |
| US54022904P | 2004-01-29 | 2004-01-29 | |
| EP04715001.6A EP1603570B9 (en) | 2003-02-26 | 2004-02-26 | Aminoheteroaryl compounds as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2476667T3 true DK2476667T3 (da) | 2014-09-15 |
Family
ID=32930516
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12163855.5T DK2476667T3 (da) | 2003-02-26 | 2004-02-26 | Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer |
| DK04715001.6T DK1603570T5 (da) | 2003-02-26 | 2004-02-26 | Aminoheteroarylforbindelser som proteinkinaseinhibitorer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04715001.6T DK1603570T5 (da) | 2003-02-26 | 2004-02-26 | Aminoheteroarylforbindelser som proteinkinaseinhibitorer |
Country Status (29)
Families Citing this family (188)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2401330T3 (es) * | 2003-02-26 | 2013-04-18 | Sugen, Inc. | Compuesto de heteroarilamino inhibidores de proteín quinasas |
| MXPA06009547A (es) * | 2004-02-23 | 2007-01-26 | Dana Farber Cancer Inst Inc | Metodo para tratar el crecimiento celular anormal usando inhibidores de c-met y m-tor. |
| CN1906167A (zh) | 2004-02-27 | 2007-01-31 | 卫材株式会社 | 新型吡啶衍生物及嘧啶衍生物(2) |
| JP2007531757A (ja) * | 2004-03-30 | 2007-11-08 | カイロン コーポレイション | 抗癌剤としての置換チオフェン誘導体 |
| US8008301B2 (en) | 2004-04-01 | 2011-08-30 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| US7632857B2 (en) * | 2004-04-01 | 2009-12-15 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| US7705025B2 (en) | 2004-08-23 | 2010-04-27 | Eli Lilly And Company | Histamine H3 receptor agents, preparation and therapeutic uses |
| HRP20100298T1 (hr) * | 2004-08-26 | 2010-06-30 | Pfizer Inc. | Enantiomerno čisti aminoheteroarilni spojevi kao inhibitori proteinskih kinaza |
| EP1786777A1 (en) * | 2004-08-26 | 2007-05-23 | Pfizer, Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
| CA2577937C (en) * | 2004-08-26 | 2010-12-21 | Pfizer Inc. | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| MX2007002247A (es) * | 2004-08-26 | 2007-04-20 | Pfizer | Biotransformacion enantioselectiva para la preparacion de intermedios de inhibidores de la proteina tirosina quinasa. |
| GT200600042A (es) * | 2005-02-10 | 2006-09-27 | Aventis Pharma Inc | Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a |
| US20090163476A1 (en) * | 2005-03-03 | 2009-06-25 | Sirtris Pharmaceuticals, Inc. | N-Phenyl Benzamide Derivatives as Sirtuin Modulators |
| ZA200709626B (en) * | 2005-05-13 | 2009-02-25 | Lexicon Pharmaceuticals Inc | Multicyclic compounds and methods of their use |
| US8093401B2 (en) * | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US7855289B2 (en) * | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| PL1910384T3 (pl) * | 2005-08-04 | 2013-03-29 | Sirtris Pharmaceuticals Inc | Pochodne imidazo[2,1-b]tiazolu jako związki modulujące sirtuinę |
| US8088928B2 (en) * | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| DK1889836T3 (da) | 2005-08-24 | 2013-08-19 | Eisai R&D Man Co Ltd | Hidtil ukendt pyridinderivat og pyrimidinderivat |
| PL1963302T3 (pl) * | 2005-12-05 | 2013-06-28 | Pfizer Prod Inc | Polimorfy inhibitora c-Met/HGFR |
| DE602006018354D1 (de) * | 2005-12-05 | 2010-12-30 | Pfizer Prod Inc | Verfahren zur behandlung von abnormalem zellwachstum |
| PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| KR20080110783A (ko) | 2006-03-07 | 2008-12-19 | 어레이 바이오파마 인크. | 헤테로바이시클릭 피라졸 화합물 및 사용 방법 |
| ES2336625T3 (es) * | 2006-03-22 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos. |
| EP2450437B1 (en) | 2006-04-14 | 2017-05-17 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| JP2009538317A (ja) * | 2006-05-26 | 2009-11-05 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ |
| CA2655128A1 (en) * | 2006-06-08 | 2007-12-21 | Array Biopharma Inc. | Quinoline compounds and methods of use |
| WO2008021781A1 (en) | 2006-08-07 | 2008-02-21 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
| CA2661333C (en) | 2006-08-23 | 2014-08-05 | Eisai R&D Management Co., Ltd. | Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
| US7790885B2 (en) * | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| WO2008042867A2 (en) * | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
| CL2007003049A1 (es) | 2006-10-23 | 2008-05-16 | Cephalon Inc Pharmacopeia Drug | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. |
| GB0621607D0 (en) * | 2006-10-31 | 2006-12-06 | Chroma Therapeutics Ltd | Inhibitors of c-Met |
| SI2497470T1 (sl) | 2006-11-22 | 2016-02-29 | Incyte Holdings Corporation | Imidazotriazini in imidazopirimidini kot inhibitorji kinaz |
| CA2672167C (en) | 2006-12-14 | 2016-01-26 | Bayer Schering Pharma Aktiengesellschaft | Dihydropyridine derivatives useful as protein kinase inhibitors |
| EP2120578B1 (en) * | 2007-01-19 | 2014-11-19 | Xcovery, INC. | Kinase inhibitor compounds |
| JPWO2008087736A1 (ja) * | 2007-01-19 | 2010-05-06 | 宇部興産株式会社 | アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法 |
| EP2851091B1 (en) * | 2007-04-13 | 2017-12-27 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer resistant to ERBB therapeutics |
| MX2009011210A (es) * | 2007-04-16 | 2009-10-30 | Abbott Lab | Inhibidores de mcl1 de indol 7-no sustituido. |
| US8263585B2 (en) | 2007-05-04 | 2012-09-11 | Novartis Ag | Organic compounds |
| TW200916472A (en) * | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| ES2394126T3 (es) * | 2007-07-26 | 2013-01-22 | Novartis Ag | Derivados de pirimidina útiles para el tratamiento de estados inflamatorios o alérgicos |
| EP2198018B1 (en) | 2007-09-13 | 2013-11-20 | Codexis, Inc. | Ketoreductase polypeptides for the reduction of acetophenones |
| MX2010004487A (es) * | 2007-10-23 | 2010-05-05 | Allergan Inc | Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular. |
| CN101918371A (zh) * | 2007-11-01 | 2010-12-15 | 西特里斯药业公司 | 作为瑟土因调节剂的酰胺衍生物 |
| BRPI0820377A2 (pt) * | 2007-11-08 | 2015-05-19 | Sirtris Pharmaceutical Inc | Tiazolopiridinas solubilizadas |
| JP2009132660A (ja) | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| WO2009073224A1 (en) * | 2007-12-07 | 2009-06-11 | Ambit Biosciences Corp. | Methods of treating certain diseases using pyrimidine derivatives |
| US20090227556A1 (en) * | 2008-01-31 | 2009-09-10 | Eisai R&D Management Co., Ltd. | Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives |
| JPWO2009096198A1 (ja) * | 2008-02-01 | 2011-05-26 | 一般社団法人ファルマＩｐ | 新規ビアリール誘導体 |
| JP2011511005A (ja) | 2008-02-04 | 2011-04-07 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | ２−アミノピリジン系キナーゼ阻害薬 |
| AR070317A1 (es) | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
| WO2009104520A1 (ja) * | 2008-02-18 | 2009-08-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | フェノキシピリジン誘導体の製造方法（２） |
| US20110092452A1 (en) * | 2008-03-05 | 2011-04-21 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
| US8268834B2 (en) * | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
| FR2928924B1 (fr) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
| FR2928923B1 (fr) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
| FR2928922B1 (fr) | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique |
| WO2009151800A1 (en) * | 2008-05-07 | 2009-12-17 | Merck & Co., Inc. | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| WO2009143211A2 (en) | 2008-05-21 | 2009-11-26 | Incyte Corporation | Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
| KR101691640B1 (ko) | 2008-06-19 | 2016-12-30 | 엑스커버리 홀딩 컴퍼니 엘엘씨 | 키나아제 억제제 화합물로서의 치환된 피리다진 카르복사마이드 화합물 |
| KR20110068987A (ko) * | 2008-08-29 | 2011-06-22 | 제넨테크, 인크. | Ｖｅｇｆ-비의존적 종양의 진단 및 치료 |
| WO2010046780A2 (en) * | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| WO2010059771A1 (en) | 2008-11-20 | 2010-05-27 | Osi Pharmaceuticals, Inc. | Substituted pyrrolo[2,3-b]-pyridines and-pyrazines |
| US8367679B2 (en) * | 2008-12-09 | 2013-02-05 | Merck Sharp & Dohme Corp. | Biaryl carboxamides |
| HUE036068T2 (hu) | 2008-12-19 | 2018-06-28 | Vertex Pharma | ATR kináz gátlószereiként alkalmazható pirazinszármazékok |
| PE20120057A1 (es) | 2008-12-19 | 2012-02-24 | Sirtris Pharmaceuticals Inc | Compuestos de tiazolopiridina moduladores de sirtuina |
| JP2012102018A (ja) * | 2009-03-03 | 2012-05-31 | Astellas Pharma Inc | アミド化合物 |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| DE102009056886A1 (de) | 2009-12-03 | 2011-06-09 | Bayer Schering Pharma Aktiengesellschaft | cMet-Inhibitoren zur Behandlung der Endometriose |
| US8487096B2 (en) | 2010-02-03 | 2013-07-16 | Incyte Corporation | Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors |
| CA2796967C (en) | 2010-05-04 | 2015-12-01 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
| NZ603477A (en) | 2010-05-12 | 2014-09-26 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
| US9062008B2 (en) * | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| EP2569315A1 (en) | 2010-05-14 | 2013-03-20 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
| AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| MX2012014776A (es) | 2010-06-25 | 2013-01-29 | Eisai R&D Man Co Ltd | Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados. |
| US9120752B2 (en) | 2010-07-16 | 2015-09-01 | Purdue Pharma, L.P. | Pyridine compounds as sodium channel blockers |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| BR112013008523B1 (pt) | 2010-10-08 | 2021-12-07 | Xcovery Holdings, Inc | Compostos de piridazina carboxamida substituídos e usos dos mesmos para tratar câncer, uma doença de proliferação, uma doença neurológica, uma doença psiquiátrica, obesidade, diabetes ou doença cardiovascular |
| EP2646448B1 (en) | 2010-11-29 | 2017-08-30 | OSI Pharmaceuticals, LLC | Macrocyclic kinase inhibitors |
| GB201021103D0 (en) * | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
| JP5681819B2 (ja) | 2011-02-11 | 2015-03-11 | バットマーク・リミテッド | 吸入器コンポーネント |
| EP2678021A4 (en) * | 2011-02-24 | 2015-07-01 | Jiangsu Hansoh Pharmaceutical | PHOSPHORUS COMPOUNDS AS A PROTEIN KINASE INHIBITOR |
| US9145390B2 (en) | 2011-03-03 | 2015-09-29 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
| JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| BR112013028895A2 (pt) | 2011-05-10 | 2016-08-09 | Bayer Ip Gmbh | (tio)carbonilamidinas bicíclicas |
| WO2012158658A1 (en) | 2011-05-16 | 2012-11-22 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
| EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| US9226923B2 (en) * | 2011-07-27 | 2016-01-05 | Nanjing Allgen Pharma Co. Ltd. | Spirocyclic molecules as protein kinase inhibitors |
| AU2012291744A1 (en) | 2011-08-02 | 2014-02-20 | Pfizer Inc. | Crizotinib for use in the treatment of cancer |
| CN103957917A (zh) | 2011-09-30 | 2014-07-30 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
| WO2013049726A2 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of atr kinase |
| ME02630B (me) | 2012-03-06 | 2017-06-20 | Pfizer | Makrociklički derivati, namijenjeni liječenju proliferativnih bolesti |
| US9206127B2 (en) | 2012-03-16 | 2015-12-08 | Purdue Pharm, L.P. | Substituted pyridines as sodium channel blockers |
| NZ726671A (en) | 2012-04-05 | 2018-04-27 | Vertex Pharma | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| US10301290B2 (en) | 2012-04-13 | 2019-05-28 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN103387535B (zh) * | 2012-05-10 | 2016-06-01 | 广东东阳光药业有限公司 | 取代的炔基吡啶化合物及其使用方法和用途 |
| WO2013177092A1 (en) * | 2012-05-23 | 2013-11-28 | Sunshine Lake Pharma Co., Ltd. | Substituted alkynyl pyridine compounds and methods of use |
| GB201211310D0 (en) * | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| BR112014032346A2 (pt) | 2012-06-26 | 2017-06-27 | Del Mar Pharmaceuticals | métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes |
| CN104603620B (zh) | 2012-09-24 | 2018-02-23 | 文塔纳医疗系统公司 | 使用间变性淋巴瘤激酶(alk)作为标志物鉴定治疗响应性非小细胞肺癌的方法 |
| US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
| US20150299170A1 (en) * | 2012-11-21 | 2015-10-22 | Concert Pharmaceuticals, Inc. | Fluoro-derivatives of pyrazole-substituted amino-heteroaryl compounds |
| EP4534538A3 (en) | 2012-12-07 | 2025-06-11 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
| EP2937337A4 (en) | 2012-12-21 | 2016-06-22 | Eisai R&D Man Co Ltd | AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF |
| WO2014117718A1 (zh) * | 2013-02-02 | 2014-08-07 | 正大天晴药业集团股份有限公司 | 取代的2-氨基吡啶类蛋白激酶抑制剂 |
| WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| JP2016519684A (ja) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| WO2015034729A1 (en) * | 2013-09-05 | 2015-03-12 | Calitor Sciences, Llc | Substituted pyridine compounds and methods of use |
| US20160214961A1 (en) * | 2013-09-10 | 2016-07-28 | Shilpa Medicare Limited | Novel salts of crizotinib and their preparation |
| RU2550346C2 (ru) | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| WO2015046653A1 (ko) | 2013-09-30 | 2015-04-02 | 한국화학연구원 | 신규한 트리아졸로 피라진 유도체 및 그의 용도 |
| WO2015069922A2 (en) | 2013-11-06 | 2015-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| CA2932757C (en) | 2013-12-06 | 2023-10-31 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| JP6820097B2 (ja) | 2013-12-20 | 2021-01-27 | サギメット バイオサイエンシーズ インコーポレイテッド | 脂質合成の複素環式モジュレータ及びその組み合わせ |
| CN103755627B (zh) * | 2014-01-09 | 2016-02-17 | 定陶县友帮化工有限公司 | 2-氨基-3-羟基-5-氯吡啶的合成方法 |
| TWI672141B (zh) | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ｒｏｓ１突變癌細胞之分子 |
| MX2016012285A (es) | 2014-03-24 | 2017-01-23 | Genentech Inc | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. |
| US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
| EP3137074B1 (en) * | 2014-04-29 | 2020-08-05 | Emory University | Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto |
| WO2015172747A1 (en) * | 2014-05-16 | 2015-11-19 | Zhaoyin Wang | Spirocyclic molecules as mth1 inhibitors |
| RU2719583C2 (ru) | 2014-06-05 | 2020-04-21 | Вертекс Фармасьютикалз Инкорпорейтед | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| CN106661064B (zh) * | 2014-08-07 | 2019-10-15 | 江苏豪森药业集团有限公司 | 一种抗癌化合物的新晶型及其制备方法和用途 |
| WO2016028971A1 (en) | 2014-08-21 | 2016-02-25 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| KR102329681B1 (ko) | 2014-08-28 | 2021-11-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| ES2879441T3 (es) | 2014-10-13 | 2021-11-22 | Atrin Pharmaceuticals LLC | Inhibidores de proteína quinasas relacionados con ataxia telangiectasia y RAD3 (ATR) |
| GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| US10662183B2 (en) | 2014-11-07 | 2020-05-26 | The Regents Of The University Of Michigan | Inhibitors of myocardin-related transcription factor and serum response factor (MRTF/SRF)-mediated gene transcription and methods for use of the same |
| JP6744309B2 (ja) | 2014-12-02 | 2020-08-19 | イグニタ，インコーポレイテッド | 神経芽細胞腫の治療のための併用 |
| EP4599890A3 (en) | 2015-01-13 | 2025-10-29 | Kyoto University | Sunitinib for preventing and/or treating amyotrophic lateral sclerosis |
| DK3263106T3 (da) | 2015-02-25 | 2024-01-08 | Eisai R&D Man Co Ltd | Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| EP3307725A1 (en) | 2015-06-11 | 2018-04-18 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
| WO2016204193A1 (ja) | 2015-06-16 | 2016-12-22 | 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ | 抗がん剤 |
| US10405627B2 (en) * | 2015-07-14 | 2019-09-10 | Michael Charles Boland, III | Luggage with fold out table |
| EP3338779B1 (en) | 2015-08-20 | 2021-06-30 | Eisai R&D Management Co., Ltd. | Lenvatinib in combination with etoposide and ifosfamide for use in treating a tumor |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| KR20180096621A (ko) | 2015-12-18 | 2018-08-29 | 이그니타, 인코포레이티드 | 암의 치료용 조합물 |
| WO2017161004A1 (en) * | 2016-03-15 | 2017-09-21 | University Of South Florida | PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS |
| WO2017180723A1 (en) | 2016-04-12 | 2017-10-19 | Atrin Pharmaceuticals LLC | Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| EP3463355B1 (en) * | 2016-05-26 | 2024-08-28 | Sonic Master Limited | Modulators of dux4 for regulation of muscle function |
| TWI646094B (zh) | 2016-06-01 | 2019-01-01 | 大陸商貝達藥業股份有限公司 | Crystal form of inhibitory protein kinase active compound and application thereof |
| JP7120549B2 (ja) * | 2016-12-15 | 2022-08-17 | 小野薬品工業株式会社 | Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ |
| CN106866627B (zh) * | 2017-01-24 | 2021-09-14 | 南方医科大学 | 3-(1-(氨基吡啶氧基)乙基)苯甲酰胺衍生物及其合成方法和应用 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| CA3061888A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| WO2019018584A1 (en) | 2017-07-18 | 2019-01-24 | GiraFpharma LLC | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| MX2020000693A (es) | 2017-07-18 | 2020-07-29 | Nuvation Bio Inc | Compuestos de 1,8-naftiridinona, y usos de los mismos. |
| IL271759B2 (en) | 2017-07-19 | 2024-01-01 | Ignyta Inc | Pharmaceutical preparations that include anthraxtinib |
| EP3697390A1 (en) | 2017-10-17 | 2020-08-26 | Ignyta, Inc. | Pharmaceutical compositions and dosage forms |
| CN107794282B (zh) * | 2017-11-20 | 2020-12-25 | 浙江工业大学 | 一种克唑替尼手性中间体的制备方法及菌株 |
| WO2019154665A1 (en) * | 2018-02-07 | 2019-08-15 | Basf Se | New pyridine carboxamides |
| PL3749646T3 (pl) * | 2018-03-15 | 2022-07-25 | Fujian Haixi Pharmaceuticals Co., Ltd | Związki heteroarylowe jako inhibitor kinazy |
| CN110372664A (zh) * | 2018-04-13 | 2019-10-25 | 华东理工大学 | 选择性jak2抑制剂及其应用 |
| CN110396088B (zh) | 2018-04-25 | 2024-03-12 | 珠海宇繁生物科技有限责任公司 | Hpk1激酶抑制剂、制备方法及其应用 |
| WO2019206049A1 (en) * | 2018-04-25 | 2019-10-31 | Zhuhai Yufan Biotechnologies Co., Ltd | Hpk1 inhibitors, preparation method and application thereof |
| CN108947895B (zh) * | 2018-08-22 | 2021-09-24 | 肇庆中彩机电技术研发有限公司 | 一种抗癌活性的化合物 |
| JP2022517419A (ja) | 2019-01-18 | 2022-03-08 | ニューベイション・バイオ・インコーポレイテッド | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| EP3911325A4 (en) * | 2019-01-18 | 2022-10-12 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
| JP2022523473A (ja) | 2019-01-18 | 2022-04-25 | ニューベイション・バイオ・インコーポレイテッド | １，８－ナフチリジジノン化合物およびそれらの使用 |
| US12240829B2 (en) | 2019-03-20 | 2025-03-04 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, and uses related thereto |
| WO2020228747A1 (en) | 2019-05-14 | 2020-11-19 | Teligene Ltd | Substituted macrocycles useful as kinase inhibitors |
| KR102426921B1 (ko) | 2019-09-24 | 2022-07-29 | 주식회사 이노보테라퓨틱스 | 헤테로아릴아미도피리딘올 유도체 및 이를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
| CN112552293A (zh) * | 2019-09-25 | 2021-03-26 | 珠海宇繁生物科技有限责任公司 | 一种protac小分子化合物及其应用 |
| KR102344185B1 (ko) * | 2020-02-26 | 2021-12-27 | 계명대학교 산학협력단 | 신규한 Pim 키나아제 억제제 및 이의 용도 |
| CN113493437B (zh) * | 2020-04-03 | 2022-07-26 | 中国药科大学 | 含苯并咪唑结构的化合物及其制备方法和用途 |
| WO2021196655A1 (zh) * | 2020-04-03 | 2021-10-07 | 中国药科大学 | 含苯并咪唑结构的化合物及其制备方法与用途 |
| EP4433445A1 (en) * | 2021-11-15 | 2024-09-25 | The Broad Institute, Inc. | Compounds, compositions, and methods for inducing antimicrobial intracellular activity and for preventing and treating microbial infections |
| IL317839A (en) | 2022-07-04 | 2025-02-01 | Chugai Pharmaceutical Co Ltd | Combination drug |
| AU2023334709A1 (en) | 2022-08-30 | 2025-03-13 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725601A (en) | 1985-06-04 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers |
| US4966849A (en) | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
| US5217999A (en) | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5326905A (en) | 1990-04-02 | 1994-07-05 | Pfizer Inc. | Benzylphosphonic acid tyrosine kinase inhibitors |
| US5302606A (en) | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| EP0584222B1 (en) | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| WO1992021660A1 (en) | 1991-05-29 | 1992-12-10 | Pfizer, Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| GB9201693D0 (en) | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
| ATE295420T1 (de) | 1992-02-06 | 2005-05-15 | Chiron Corp | Marker für krebs und biosynthetisches bindeprotein dafür |
| SK283413B6 (sk) | 1992-08-06 | 2003-07-01 | Warner-Lambert Company | 2-Tioindoly, 2-indolíntióny a polysulfidy, ich selénové analógy a farmaceutické prostriedky na ich báze |
| US5330992A (en) | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| JP3398382B2 (ja) | 1992-10-28 | 2003-04-21 | ジェネンテク，インコーポレイテッド | 血管内皮細胞増殖因子アンタゴニスト |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5521190A (en) * | 1993-05-27 | 1996-05-28 | Fmc Corporation | Insecticidal pterdines and 8-deazapteridines |
| JPH07109260A (ja) * | 1993-10-12 | 1995-04-25 | Fuji Photo Film Co Ltd | ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法 |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| ATE198326T1 (de) | 1995-04-20 | 2001-01-15 | Pfizer | Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| ES2183905T3 (es) | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
| IL125954A (en) | 1996-03-05 | 2003-06-24 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect |
| PT912559E (pt) | 1996-07-13 | 2003-03-31 | Glaxo Group Ltd | Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| WO1998002437A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
| IL127567A0 (en) | 1996-07-18 | 1999-10-28 | Pfizer | Phosphinate based inhibitors of matrix metalloproteases |
| EA199900139A1 (ru) | 1996-08-23 | 1999-08-26 | Пфайзер, Инк. | Производные арилсульфониламиногидроксамовой кислоты |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| AU5131998A (en) | 1997-01-06 | 1998-08-03 | Pfizer Inc. | Cyclic sulfone derivatives |
| WO1998033768A1 (en) | 1997-02-03 | 1998-08-06 | Pfizer Products Inc. | Arylsulfonylamino hydroxamic acid derivatives |
| CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| JP3710489B2 (ja) | 1997-02-11 | 2005-10-26 | ファイザー・インク | アリールスルホニルヒドロキサム酸誘導体 |
| SE9700661D0 (sv) * | 1997-02-25 | 1997-02-25 | Astra Ab | New compounds |
| EP0984930B1 (en) | 1997-05-07 | 2005-04-06 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| EP0984692A4 (en) | 1997-05-30 | 2001-02-21 | Merck & Co Inc | ANGIOGENESIS INHIBITORS |
| AU8816298A (en) | 1997-08-22 | 1999-03-16 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
| HRP20000286A2 (en) | 1997-11-11 | 2000-12-31 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| SE9801526D0 (sv) * | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
| SK287132B6 (sk) | 1998-05-29 | 2009-12-07 | Sugen, Inc. | Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu |
| US20010002396A1 (en) * | 1998-07-16 | 2001-05-31 | Charles Achkar | Compositions and methods of treating skin conditions |
| EE200100425A (et) | 1999-02-11 | 2002-12-16 | Pfizer Products Inc. | Heteroarüül-asendatud kinoliin-2-ooni derivaadid kui vähivastased vahendid |
| GB9908410D0 (en) | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
| CA2383546A1 (en) | 1999-06-30 | 2001-01-04 | William H. Parsons | Src kinase inhibitor compounds |
| HN2001000008A (es) * | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| CA2399358C (en) | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| YU61002A (sh) | 2000-02-16 | 2005-06-10 | Neurogen Corporation | Supstituisani arilpirazini |
| MXPA03000056A (es) | 2000-07-07 | 2003-07-14 | Tufts College | Compuestos de tetraciclina sustituidos en posicion 7. |
| DK1330452T3 (da) * | 2000-09-20 | 2009-03-16 | Ortho Mcneil Janssen Pharm | Pyrazinderivater som modulatorer af tyrosinkinaser |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| JP4064818B2 (ja) * | 2001-02-12 | 2008-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | ６−置換ピリド−ピリミジン類 |
| US6825198B2 (en) * | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| EP1446387B1 (en) | 2001-11-21 | 2009-11-04 | Pharmacia & Upjohn Company LLC | Substituted aryl 1,4-pyrazine derivatives |
| ES2401330T3 (es) * | 2003-02-26 | 2013-04-18 | Sugen, Inc. | Compuesto de heteroarilamino inhibidores de proteín quinasas |
| HRP20100298T1 (hr) | 2004-08-26 | 2010-06-30 | Pfizer Inc. | Enantiomerno čisti aminoheteroarilni spojevi kao inhibitori proteinskih kinaza |
| CA2577937C (en) | 2004-08-26 | 2010-12-21 | Pfizer Inc. | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| US9672526B2 (en) | 2012-03-13 | 2017-06-06 | American Express Travel Related Services Company, Inc. | Systems and methods for tailoring marketing |
| US10884952B2 (en) | 2016-09-30 | 2021-01-05 | Intel Corporation | Enforcing memory operand types using protection keys |
| JP6943759B2 (ja) | 2017-12-28 | 2021-10-06 | 株式会社東海理化電機製作所 | シフト装置 |
-
2004
- 2004-02-26 ES ES04715001T patent/ES2401330T3/es not_active Expired - Lifetime
- 2004-02-26 ME MEP-528/08A patent/MEP52808A/xx unknown
- 2004-02-26 CN CN201310167961.7A patent/CN103265477B/zh not_active Expired - Lifetime
- 2004-02-26 MX MXPA05009063A patent/MXPA05009063A/es active IP Right Grant
- 2004-02-26 OA OA1200500243A patent/OA13151A/en unknown
- 2004-02-26 BR BRPI0407827A patent/BRPI0407827B8/pt not_active IP Right Cessation
- 2004-02-26 PT PT121638555T patent/PT2476667E/pt unknown
- 2004-02-26 CA CA2517256A patent/CA2517256C/en not_active Expired - Lifetime
- 2004-02-26 PT PT47150016T patent/PT1603570E/pt unknown
- 2004-02-26 KR KR1020057015999A patent/KR101106905B1/ko not_active Expired - Lifetime
- 2004-02-26 WO PCT/US2004/005495 patent/WO2004076412A2/en not_active Ceased
- 2004-02-26 NZ NZ541861A patent/NZ541861A/en not_active IP Right Cessation
- 2004-02-26 GE GEAP20048993A patent/GEP20084341B/en unknown
- 2004-02-26 RS YU20050708A patent/RS53118B/sr unknown
- 2004-02-26 EP EP12163855.5A patent/EP2476667B1/en not_active Expired - Lifetime
- 2004-02-26 EA EA200501236A patent/EA010727B1/ru active Protection Beyond IP Right Term
- 2004-02-26 JP JP2006503845A patent/JP4695588B2/ja not_active Expired - Lifetime
- 2004-02-26 EP EP04715001.6A patent/EP1603570B9/en not_active Expired - Lifetime
- 2004-02-26 PL PL378759A patent/PL216368B1/pl unknown
- 2004-02-26 ES ES12163855.5T patent/ES2502490T3/es not_active Expired - Lifetime
- 2004-02-26 AP AP2005003383A patent/AP2114A/xx active
- 2004-02-26 DK DK12163855.5T patent/DK2476667T3/da active
- 2004-02-26 HR HRP20050714AA patent/HRP20050714B1/hr not_active IP Right Cessation
- 2004-02-26 AU AU2004215428A patent/AU2004215428B2/en active Active
- 2004-02-26 DK DK04715001.6T patent/DK1603570T5/da active
- 2004-02-26 US US10/786,610 patent/US7230098B2/en not_active Expired - Lifetime
-
2005
- 2005-08-15 IL IL170291A patent/IL170291A/en active Protection Beyond IP Right Term
- 2005-08-18 IS IS7990A patent/IS2910B/is unknown
- 2005-08-26 EC EC2005005988A patent/ECSP055988A/es unknown
- 2005-08-26 TN TNP2005000208A patent/TNSN05208A1/fr unknown
- 2005-08-26 MA MA28457A patent/MA27713A1/fr unknown
- 2005-09-01 NO NO20054080A patent/NO332188B1/no unknown
-
2006
- 2006-11-14 US US11/598,765 patent/US8106197B2/en active Active
-
2013
- 2013-03-19 CY CY20131100229T patent/CY1113837T1/el unknown
-
2014
- 2014-08-20 CY CY20141100664T patent/CY1115472T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2476667T3 (da) | Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer | |
| DK1784396T3 (da) | Pyrazol-substituerede aminoheteroaryl-forbindelser som proteinkinase-inhibitorer | |
| DK1786785T3 (da) | Enantiomerisk rene aminoheteroaryl-forbindelser som proteinkinasehæmmere | |
| DE602004025258D1 (de) | Aminotriazol-verbindungen als proteinkinase-hemmer | |
| NO20041887L (no) | Benzomidazoler anvendelige som proteinkinase-inhibitorer | |
| DK1881976T3 (da) | Substituerede amidderivater som proteinkinaseinhibitorer | |
| DK1585749T3 (da) | Diazepinoindol-derivater som kinaseinhibitorer | |
| DK1713806T3 (da) | Forbindelser og sammensætninger som proteinkinaseinhibitorer | |
| IL173380A0 (en) | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | |
| DK1699797T3 (da) | Pyrrolotriazinforbindelser som kinasehæmmere | |
| DK1610780T4 (da) | Cykliske protein-tyrosin-kinasehæmmere | |
| NO20032703D0 (no) | Pyrazolforbindelser nyttige som proteinkinaseinhibitorer | |
| NO20031188D0 (no) | Pyrazolforbindelser nyttige som proteinkinaseinhibitorer | |
| NO20035728D0 (no) | Pyrrolopyrimidiner som proteinkinaseinhibitorer | |
| SI1603570T1 (sl) | Spojine aminoheteroarila kot zaviralci proteinkinaze | |
| DK1317448T4 (da) | Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer |